HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $38 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintains a $38 price target.
June 15, 2023 | 2:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Iovance Biotherapeutics and maintains a $38 price target.
The reiterated Buy rating and maintained $38 price target by HC Wainwright & Co. analyst Joseph Pantginis is a positive signal for Iovance Biotherapeutics. This reaffirms the analyst's confidence in the company's potential, which could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100